Pfizer

4. Pfizer
2013 sales: $3.97 billion

Pfizer's ($PFE) got the top-selling vaccine in the world in pneumococcal conjugate Prevnar 13--and not a whole lot else. But even without a vaccine lineup outside of its Prevnar franchise, that jab's top-line power was enough to push Pfizer into the top 5. Prevnar 13 churned out $3.76 billion for Pfizer in 2013, and that's only set to increase, with Evaluate Pharma predicting $6.08 billion in sales for the vaccine come 2020.

But CEO Ian Read has been expressing interest in expanding beyond Prevnar for a while now, and if all goes right for Pfizer, by that time the best-selling shot will have at least one companion in the drug giant's vaccine stable. Last month, Pfizer submitted a Biologics License Application (BLA) for its meningitis B candidate, dubbed rLP2086, to the FDA.

If approved, the vaccine may have some company: The same day Pfizer handed over its BLA, Novartis ($NVS) handed one over for its own vaccine, Bexsero, already on the market in Europe. All things considered, ISI Group analyst Mark Schoenebaum says Pfizer's jab could yield about $225 million in peak sales by 2019, conservatively speaking.

And if Pfizer revives deal talks with AstraZeneca ($AZN)--as some analysts expect it will--that could bring along hopes for padding its vaccine unit even more. AZ boasts FluMist, a nasal spray that protects against seasonal flu; recently a CDC committee recommended the spray over flu shots in children, which should give sales a boost.

For more:
Prevnar use in seniors is cost-effective now, CDC says. But will it last?
Pfizer puts the heat on Novartis with FDA MenB filing
Pfizer teams up to lift adult vaccination rates--and Prevnar sales, too
AstraZeneca merger could bring the vaccines heft Pfizer's been looking for

Pfizer
Read more on

Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.